Resource Development Core

资源开发核心

• 批准号: 10746571
• 负责人: Javier A. Neyra
• 金额: $ 14.65万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10746571
• 关键词: Acceleration; Acute Renal Failure with Renal Papillary Necrosis; Address; Adoption; Anatomy; Animal Model; Area; Artificial Intelligence; Big Data; Biologic Characteristic; Biological; Biological Assay; Biology; Caring; Classification; Clinical; Clinical Research; Data; Data Analyses; Development; Disease; Electronic Health Record; Etiology; Evaluation; Feedback; Focus Groups; Future; Goals; Heterogeneity; Image; Incubated; Incubators; Individual; Infrastructure; Institution; Interview; Kidney; Leadership; Learning; Magnetic Resonance Imaging; Methodology; Methods; Microfluidics; Molecular; Pathway interactions; Patients; Peptides; Persons; Phenotype; Physiology; Policies; Positron-Emission Tomography; Procedures; Protocols documentation; Reproducibility; Research; Research Methodology; Research Personnel; Resolution; Resource Development; Resources; Risk; Services; Sustainable Development; System; Technology; Testing; Thinking; Time; Tissues; Translational Research; Validation; biomedical resource; data harmonization; data management; digital; federated learning; health inequalities; high standard; implementation science; improved; in vivo imaging; innovation; metabolomics; multi-task learning; new technology; novel; novel therapeutics; patient oriented; phenotypic data; pre-clinical; pre-clinical research; preclinical imaging; research clinical testing; response; small molecule; tool; translational applications; treatment effect

Innovations to mitigate the global burden of acute kidney injury (AKI) require catalyzers that network investigators and provide them with resources that facilitate discovery, translation and implementation science to impact bedside care, improve policy and dismantle health inequalities. The overarching objective of the Resource Development Core is to incubate novel and strategic approaches to continuously support AKI research across a diverse universe of investigators in the O'Brien Kidney Consortium. This Core will provide a dynamic resource and platform to develop, test and refine innovations that could accelerate pre-clinical and clinical research and then can be offered as part of the Biomedical Resource Cores. The initial focus of this Core will be centered in advanced and quantitative AKI biological characterization and big data analyses. In the pre-clinical area, novel analytical approaches in metabolomics and molecular and functional in vivo imaging will be incubated to probe unique biological characteristics of disease development. In the clinical area, tools for multi-institutional Electronic Health Record (EHR) data management and harmonization and a novel federated learning platform to evaluate Artificial Intelligence (AI)-based tools will be developed. These development areas will be frequently evaluated to assure that the selected tools to be refined or developed are relevant to patients and investigators, and use the most advanced technologies to maintain high standards of validation, reproducibility and transferability tailoring the growing investigator's needs with a pathway to be offered in the Biomedical Cores in the future. To continue to drive innovations in AKI research, the following Specific Aims are proposed. In Aim 1, we will develop an incubator for novel technologies to support pre-clinical research in AKI. Specifically, in Aim 1A, we will develop tools for the examination of the disturbed distribution of small molecules and peptides in AKI. We will develop novel microfluidic methods aimed at high resolution molecular cartography in kidney tissue. In Aim 1B, we will develop molecular and functional kidney-specific imaging and image-analysis approaches in pre-clinical animal models of AKI. Probing for longitudinal evaluations of tissue- scale biological changes with translational positron emission tomography (PET) and magnetic resonance imaging (MRI) will elucidate key molecular, functional, and anatomical alterations during AKI development and in response to novel therapeutics. In Aim 2, we will develop an incubator for digital workspace technologies to support EHR data analyses in AKI. This will include enhancements in existing collaborative digital workspaces to support EHR data management and harmonization (Aim 2A) and the development of a novel federated multi- task learning platform to evaluate AI-based tools (Aim 2B). These aims are forward-thinking to enable novel methodologies to better understand the pathobiology and heterogeneity of AKI.

减轻全球急性肾脏损伤负担（AKI）的创新需要催化剂 调查人员并为他们提供促进发现，翻译和实施科学的资源 影响床旁护理，改善政策并消除健康不平等。总体目标 资源开发核心是孵化新颖的战略方法，以不断支持AKI 在奥布莱恩肾脏财团中的各种研究者宇宙中进行研究。这个核心将提供 开发，测试和完善创新的动态资源和平台，这些创新可能会加速前临床和 然后可以作为生物医学资源核心的一部分提供临床研究。最初的重点 核心将集中在高级和定量的AKI生物学表征和大数据分析中。在 临床前区域，代谢组学的新分析方法以及分子和功能在体内成像的方法 孵育以探测疾病发展的独特生物学特征。在临床领域，工具 多机构电子健康记录（EHR）数据管理和协调以及一个新颖的联合 将开发评估人工智能（AI）工具的学习平台。这些发展领域 将经常评估以确保所选的要完善或开发的工具与患者有关 和研究人员，并使用最先进的技术来维持高标准的验证， 可重复性和可转让性，以在不断增长的研究人员的需求下量身 生物医学核心将来。为了继续推动AKI研究中的创新，以下具体目标 提出了。在AIM 1中，我们将开发一种新型技术的孵化器，以支持临床前研究 aki。具体而言，在AIM 1A中，我们将开发用于检查小规模分布的工具 AKI中的分子和肽。我们将开发针对高分辨率分子的新型微流体方法 肾脏组织中的制图。在AIM 1B中，我们将开发分子和功能性的肾脏特异性成像和 AKI前临床动物模型中的图像分析方法。探测组织的纵向评估 比例生物学变化，具有翻译正电子发射断层扫描（PET）和磁共振 成像（MRI）将阐明AKI发育过程中的关键分子，功能和解剖学变化 响应新型治疗学。在AIM 2中，我们将开发一个用于数字工作区技术的孵化器 支持AKI中的EHR数据分析。这将包括现有协作数字工作空间中的增强功能 支持EHR数据管理和协调（AIM 2A），并开发新的联邦多人 评估基于AI的工具的任务学习平台（AIM 2B）。这些目的是有前瞻性的，以启用小说 更好地了解AKI的病理生物学和异质性的方法。